SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Regarding the other novel antidiabetic non-insulinic drug [37], Mirarchi et al. [38] reported in a review of 13 studies the benefits of sodium-glucose cotransporter-2 inhibitors in patients with NAFLD decrease liver fat content, AST/ALT levels and liver stiffness as seen in Table 1.